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Abstract 
Background: Red blood cell invasion by the Plasmodium vivax merozoite requires interaction between the Duffy 
antigen receptor for chemokines (DARC) and the P. vivax Duffy‑binding protein II (PvDBPII). Given that the disruption 
of this interaction prevents P. vivax blood‑stage infection, a PvDBP‑based vaccine development has been well recog‑
nized. However, the polymorphic nature of PvDBPII prevents a strain transcending immune response and complicates 
attempts to design a vaccine.
Methods: Twenty‑three P. vivax clinical isolates collected from three areas of Ethiopia were sequenced at the pvdbpII 
locus. A total of 392 global pvdbpII sequences from seven P. vivax endemic countries were also retrieved from the NCBI 
archive for comparative analysis of genetic diversity, departure from neutrality, linkage disequilibrium, genetic dif‑
ferentiation, PvDBP polymorphisms, recombination and population structure of the parasite population. To establish a 
haplotype relationship a network was constructed using the median joining algorithm.
Results: A total of 110 variable sites were found, of which 44 were parsimony informative. For Ethiopian isolates there 
were 12 variable sites of which 10 were parsimony informative. These parsimony informative variants resulted in 10 
nonsynonymous mutations. The overall haplotype diversity for global isolates was 0.9596; however, the haplotype 
diversity was 0.874 for Ethiopia. Fst values for genetic revealed Ethiopian isolates were closest to Indian isolates as 
well as to Sri Lankan and Sudanese isolates but further away from Mexican, Papua New Guinean and South Korean 
isolates. There was a total of 136 haplotypes from the 415 global isolates included for this study. Haplotype prevalence 
ranged from 36.76% to 0.7%, from this 74.2% were represented by single parasite isolates. None of the Ethiopian iso‑
lates grouped with the Sal I reference haplotype. From the total observed nonsynonymous mutations 13 mapped to 
experimentally verified epitope sequences. Including 10 non‑synonymous mutations from Ethiopia. However, all the 
polymorphic regions in Ethiopian isolates were located away from DARC, responsible for junction formation.
Conclusion: The results of this study are concurrent with the multivalent vaccine approach to design an effective 
treatment. However, the presence of novel haplotypes in Ethiopian isolates that were not shared by other global 
sequences warrant further investigation.
Keywords: Plasmodium vivax, PvDBPII, DARC , Polymorphism, Mutations
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ 




1 Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis 
Ababa, Ethiopia
Full list of author information is available at the end of the article
Page 2 of 9Golassa et al. Malar J          (2021) 20:312 
Background
Of the Plasmodium species infecting human, Plasmo-
dium vivax is responsible for the most geographically 
widespread form of malaria. Once considered benign, P. 
vivax is now known to cause recurrent infections that 
can sometimes lead to severe life-threatening patholo-
gies [1, 2]. Though chemotherapies are available, there is 
as yet a vaccine due to challenges with polymorphisms 
and the presence of multiple strains in endemic regions 
that restrict strain-transcending global protection [3–6]. 
The pathological outcomes of P. vivax infection depend 
on the parasite’s ability to identify, invade human eryth-
rocytes and develop clinical levels of parasitaemia. The 
molecular mechanisms of invasion of immature red 
blood cells by P. vivax requires a Duffy Binding Protein II 
(PvDBPII) ligand, which interacts with its human recep-
tor on the surface of erythrocytes, the Duffy Antigen 
Receptor for Chemokines (DARC). As PvDBP-DARC 
interaction is critical, individuals lacking the Duffy anti-
gen on their erythrocyte surface (Duffy negatives) are 
resistant or have reduced susceptibility to P. vivax infec-
tion [7, 8]. Moreover, acquired antibodies against PvDB-
PII can inhibit PvDBP-DARC interaction and P. vivax 
invasion, partly qualifying PvDBPII as a leading asexual 
blood stage vaccine candidate against  P. vivax. How-
ever, PvDBPII like other Duffy-binding orthologues, is 
particularly polymorphic especially at its amino termi-
nal cysteine-rich region II (PvDBPII). This hampers the 
rational design of potent DBP-based vaccines and neces-
sitates the identification of globally conserved epitopes 
across parasite populations for evaluation in possible 
multivalent vaccine designs. Therefore, knowledge of the 
nature and levels of genetic polymorphisms in PvDBPII 
among global  P. vivax  isolates  is important toward vac-
cine development.
Analysis of PvDBPII protein sequences identified seven 
haplotypes represented in 60% of global P. vivax popula-
tions [9]. African isolates were poorly represented in this 
data partly due to relative dominance of  Plasmodium 
falciparum  cases in Africa and mostly Duffy-negative 
human populations that are resistant to  P. vivax  infec-
tion [10]. Though the Duffy blood group antigen  (Fya or 
 Fyb) is not expressed on red blood cells (RBCs) of the 
majority of individuals of African origin [11], low levels 
of P. vivax malaria has now been reported across much 
of Africa using sensitive molecular diagnosis methods [7, 
12–15]. This has raised questions on the expansion of the 
infection across more African population as P. falcipa-
rum is targeted and eliminated. This risk is particularly 
high in populations where transmission of P. falciparum 
and P. vivax is sympatric and at significant levels, such 
as Ethiopia and population across the Sahara. In Ethio-
pia, P. vivax accounts for almost 30% of all malaria cases 
indicating the great public health significance of this 
neglected parasite [16]. Future P. vivax vaccines based 
on PvDBPII must, therefore, assess these populations for 
global efficacy.
In Ethiopia, evidence of  pvdbpII gene amplification 
(three and eight copies) in two Duffy-negative individu-
als has been reported [17]. Worryingly, a study has also 
shown that parasites with increased pvdbpII copy num-
ber are able to infect erythrocytes even in the presence 
of naturally acquired antibodies that would have other-
wise blocked binding of PvDBP to DARC [18]. Upon this 
is antigenic variation, i.e., the ability to produce vari-
able antigens, which enables the parasite to evade host 
immunity [6]. Thus, a multivalent PvDBPII based vaccine 
will be most favorable and its design will require knowl-
edge of most strains of P. vivax circulating globally. This 
study describes genetic diversity of pvdbpII in isolates 
from Ethiopia, which is the fourth highest contributor to 
global vivax infections.
Methods
Blood samples, DNA extraction and P. vivax diagnosis
A total of 30 P. vivax samples were collected in a cross-
sectional study conducted from Nov. 2018 to Dec. 2018 
in East Shoa Zone, Ethiopia. The blood samples were 
collected from clinical malaria patients attending health 
facilities. Thick and thin blood films prepared for spe-
cies identification. Blood samples were spotted onto 
filter papers for parasite DNA extraction. Vivax malaria-
infected patients were treated by chloroquine. Genomic 
DNA was extracted from DBS using QIAamp DNA Mini 
kit (QIAGEN, Hilden, Germany) according to manufac-
turers’ protocol. DNA extracts were then used to confirm 
P. vivax infections by qPCR using the GENESIG Plasmo-
dium vivax standard kit (PrimerDesign Ltd, Chandler’s 
Ford, UK) according to manufacturers’ protocol. Cycling 
conditions on the  CFX96TM Real-Time PCR detection 
system (Bio-Rad Laboratories Ltd, California, USA) 
include enzyme activation at 95 °C for 2 m, followed by 
50 cycles of denaturation at 95 °C for 10 s and annealing/
data acquisition on the FAM channel at 60 °C for 60 s.
Amplification and sequencing of the PvDBPII
The PvDBP region was amplified using a modified ver-
sion of previously published PCR conditions [18] and 
comparing amplicons from two different forward prim-
ers (PvDBP_N1_fwd 5′- GAT AAA ACT GGG GAG GAA 
AAA GAT -3′ and PvDBP_N2_fwd 5′- CCT CGA ATG 
GTG GCA ATC CT-3′) in combination with a single 
reverse primer (PvDBP_N1_rev 5′- CTT ATC GGA TTT 
GAA TTG GTGGC-3′) to give amplicons of approxi-
mately 1243 bp and 1062 bp respectively. Final amplifica-
tion conditions contained 0.02U/µl of Q5® High-Fidelity 
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DNA Polymerase enzyme in 1X Q5® High-Fidelity DNA 
Polymerase Buffer (New England Biolabs, Hitchin, UK), 
0.2  mM dNTPs, 0.1  ng/ml of Bovine serum albumin 
(BSA), 0.5µM of the forward and reverse primers and 
5µl of template DNA. Cycling conditions were 98 °C of 
enzyme activation for 30 secs, followed by 35 cycles of 
denaturation at 98  °C for 10  s, annealing at 62  °C (for 
amplicon 1–1243 bp) or 67 °C (for amplicon 2–1062 bp) 
for 30  s, elongation at 72  °C for 60  s and a final exten-
sion at 72  °C for 120  s. Amplicons were purified using 
Sephadex G-50 (Merck, Darmstadt, Germany) and puri-
fied amplicons were then used as templates for cycle 
sequencing reaction, using the Applied Biosystems™ Big-
Dye™ Terminator v3.1 Cycle Sequencing Kit, according 
to manufacturers’ protocols. Sequences were detected 
on the SeqStudio genetic analyzer (Applied Biosystems, 
California, USA). PvdbpII sequences were successfully 
obtained for 23 Ethiopian sequences. For each isolate, 
trace files for pvdbpII were curated and assembled by 
Seqman pro in Lasergene v 15.3 (DNASTAR) to gener-
ate consensus sequences. The latter were aligned using 
ClustalW alignment algorithm in MEGA X. For com-
parative analysis, a total of 392 global pvdbpII sequences 
from 7 P. vivax endemic countries were retrieved 
from the NCBI archive. These included 100 isolates 
from India (FJ491142.1-FJ491241.1), 35 from Mexico 
(KP759780-KP759814), 12 from Myanmar (JN25576.1-
JN255587.1), 89 from PNG (AF469515-AF469602), 13 
from South Korea (JN989472.1-JN989484.1), 100 from 
Sri-lanka (GU143914-GU143949), and 43 from Sudan 
(MG805616-MG805657). The reference sequence from 
Sal-1 (DQ156512) was included in the final analysis.
Genetic diversity of pvdbpII sequences
DNA sequence polymorphisms and diversity statistics 
were analysed using DnaSP v 6.12. The following genetic 
diversity parameters were assessed: number of segregat-
ing sites (S), nucleotide diversity (π), haplotype diversity 
(Hd), average number of pair wise nucleotide differences 
(K) within the population, and total number of muta-
tions ( η ). To test if population diversity at pvdbpII devi-
ated from neutrality, Tajimas D and Fu and Lis F indices 
were calculated for the overall protein region sequenced 
as well as by scanning across the regions using the slid-
ing window approach (window size of 90  bp and a step 
size of 3  bp). Departures from neutrality were further 
assessed using the rates of synonymous (dS) and non-
synonymous (dN) mutations, estimated and compared by 
the Z-test (P < 0.05) in MEGAx using the Nei and Gojo-
bori method with jukes cantor correction and 1000 boot-
strap replications.
Linkage disequilibrium (LD), effective population 
size, probability of recombination between adjacent 
nucleotides per generation and minimum number 
of recombination events (Rm) were measured using 
DnaSP. Genetic differences between populations were 
determined using Wier and Cockerham’s Fst. To visu-
alize the global haplotype network between the iso-
lates, the median joining algorithm as implemented 
on NETWORK v10. STRU CTU RE v 2.3.4 was used to 
resolve the genetic structure of P. vivax haplotypes. For 
STRU CTU RE, data were run for values K2-K9 using 
admixture ancestry model, each run had a burn in 
period of 50,000 iterations and 100,000 Markov chain 
Monte carlo replications. The most probable K value 
was then calculated according to Evannos method by 
using the STRU CTU RE harvester website. CLUMPAK 
was used to graphically display results produced by the 
STRU CTU RE software. To investigate the effects of 
host immune pressure on the diversity of B and T cell 
epitopes, the genetic diversity in in-silico predicted 
and known B and T cell epitopes and MHC-binding 
regions in PvDBPII were examined. These epitopes 
were mapped against the tertiary structure of PvDBPII 
extracted from the Protein data bank (6R2S).and 3RRC 
which shows crystal structure of region ii from P. vivax 
Duffy binding protein (Dimerization of P. vivax DBP is 
induced upon receptor binding and drives recognition 
of DARC).
Results
High level of diversity in PvDBPII
Out of the 30 samples that tested positive for P. vivax, 
pvdbpII was successfully amplified and sequenced from 
23 P. vivax single infections as verified using qPCR. 
The 23 sequences ranged from 958 to 1190  bp. Further 
analysis was constrained to a 675 bp region that aligned 
across all isolates from Ethiopia and the global source 
from NCBI (total of 415 sequences). From these, 110 
variable sites were detected, of which 44 were parsimony 
informative. For Ethiopian isolates only, there were 12 
variable sites of which 10 were parsimony informative 
(contains at least two types of nucleotides, or at least two 
of them occur with a minimum frequency of two). These 
parsimony informative variants resulted in 10 nonsyn-
onymous mutations. Overall global isolates in this study 
showed 66 singleton mutations, i.e., observed in only one 
isolate. The overall haplotype diversity for global isolates 
was 0.9596, while for Ethiopia it was 0.874. The observed 
nucleotide diversity for Ethiopian isolates was 0.00608 
(Table 1) with highest peaks of nucleotide diversity with 
the pvdbpII coming between the middle intersection 
of the alignment (196–366) base pairs. Sliding window 
analysis reveals that nucleotide diversity (π) ranged from 
0.014 to 0.019 in this region.
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Balancing selection signatures map around PvDBPII 
immune epitopes
Overall tests for neutrality by Fu and Lis’ F and Tajimas’ 
D were positive for pvdbpII from all populations, with 
values of X and Y, respectively for Ethiopian isolates. 
Sequence diversity was heterogeneous across the region 
with highest Pi values around nucleotides 200 to 500 
(Figs. 1 and  2). Both Fu and Lis D and F tests detected 
significant positive values in Ethiopian isolates in the 
region that spans from 265–465 bp (1.5704 P < 0.10). Sig-
nificant positive values were also observed for Tajimas D 
value in the region 289–384 (1.9349 P < 0.10) for global 
isolates and 310–486 (2.0651 P < 0.05) for Ethiopian 
isolates.
The regions with higher signatures of balancing selec-
tion were dominated by non-synonymous mutations. 
The global set of isolates exhibited 30 nonsynonymous 
mutations, of which 13 mapped to epitope sequences 
(Table  2). The observed 10 non-synonymous mutations 
in Ethiopia equally mapped against regions of balancing 
selection and mapped/corresponded to experimentally 
verified epitopes.
The source of genetic variation was tested for recom-
bination using the minimum recombination events 
as implemented in DnaSP. In global P. vivax popula-
tions the minimum numbers of recombination events 
between adjacent polymorphic sites (Rm) was high in 
Indian, Myanmar and Sri Lankan isolates all of which 
were > 5 (Table  3). In compliment LD index  R2 declined 
across analysed region in Ethiopian isolates an indica-
tor of intragenic recombination as a possible means for 
increased diversity (Fig. 3).
Differentiation at PvDBPII between populations
Pairwise population Fst values at PvDBPs between the 
eight P. vivax endemic populations ranged from 0.0193 
between Sri Lanka and India to 0.3647 between South 
Korea and Mexico (Table  4). Ethiopian isolates were 
closer to Indian and Sri Lankan compared to Sudanese 
isolates despite geographic proximity between Sudan and 
Ethiopia. They were most diverged from Mexican, Papua 
New Guinean and South Korean isolates.
Nine distinct haplotypes of pvdbpII were detected in 
Ethiopian isolates (Fig.  4). Of the 9 haplotypes, 6 had 
Table 1 Nucleotide diversity parameters for pvdbpII gene in eight P. vivax endemic countries
S Segregating sites, Hd Haplotype diversity, K Average number of pair- wise nucleotide differences, π Nucleotide diversity
Countries No. of isolates S H Hd K π
Ethiopia 23 12 9 0.87352 4.08696 0.00608
India 100 36 35 0.92141 5.90222 0.00885
Mexico 35 10 7 0.55294 2.68908 0.00400
Myanmar 12 27 12 1.000 8.25758 0.001229
PNG 89 61 42 0.91267 6.29826 0.00937
S. Korea 13 14 12 0.98718 3.69231 0.00549
Sri Lanka 100 27 39 0.92242 6.54020 0.00973
Sudan 42 17 15 0.89547 4.01742 0.00598
Fig. 1 Sliding window analysis (window size 90, step size 3) for Nucleotide diversity (π) in Global (left) and Ethiopian (right) using pvdbpII sequence
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the highest frequency with 6 isolates followed by hap-
lotypes 2 with 5, haplotypes 5 and 7 had 3 isolates each 
whereas there were 2 isolates for haplotype 1, while 
the rest had one isolate each (Fig.  5). There was a total 
of 136 haplotypes from the 415 global isolates analysed. 
Haplotype prevalence ranged from 36.76% to 0.7%, with 
74.2% represented by a single parasite isolate. None of 
the Ethiopian isolates grouped with the Sal I reference 
haplotype; instead two formed their own cluster (1.47%), 
five clustered together in the dominant haplotype type 
represented in 50 isolates (36.76%) from India, Sri Lanka 
and Sudan. Another five Ethiopian isolates grouped in a 
cluster of 39 isolates from Mexico and Sudan (28.67%), 
Fig. 2 Sliding window analysis (Window size 90, step size 3) results for Departure from Neutrality using Fu and Lis F (left) and Tajimas’ D (right) for 
Ethiopian pvdbpII’ sequences
Table 2 Polymorphic regions (highlighted) that map to known 
epitopes sequences





Ia MHC class I GNFIWICKI
Ic MHC class I VLSNKFKSVKNAEK
IIa MHC class II YSVKKRLKGN
IIb MHC class II FIWICKINY
Table 3 Estimates of recombination events in pvdbpII gene in 
eight global P. vivax endemic countries
Ra recombinant parameter between adjacent sites,  Rb recombination parameter 
for whole gene, Rm minimum number of recombination events
Country (No. of isolates) Ra Rb Rm
Ethiopia (23) 0.0261 17.5 2
India (100) 0.0240 16.1 10
Mexico (35) 0.000 0.001 1
Myanmar (12) 0.2623 176 7
PNG (89) 0.0146 9.8 3
South Korea (13) 0.0741 49.7 1
Sri Lanka (100) 0.0206 13.8 9
Sudan (42) 0.0310 20.8 3
Fig. 3 Linkage disequilibrium plot of  R2 for pvdbpII gene from 
Ethiopian isolates
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three grouped with 18 isolates from Sri Lanka and Sudan 
(13.24%), further three grouped with 17 Indian and Suda-
nese isolates (12.4%), whereas four isolates formed their 
own unique single haplotype cluster each.
All the polymorphic regions in Ethiopian isolates 
were located away from the Duffy antigen receptor for 
chemokines responsible for junction formation (Addi-
tional file  1). In sharp contrast the polymorphic region 
from other isolates showed that a mutation is present in 
this critical region.
Discussion
The interaction between the Duffy antigen for chemokine 
receptors in humans and the Duffy binding protein in P. 
vivax is critical for the subsequent invasion of reticulo-
cytes. This pathway is currently the only known way the 
parasite colonizes its human host. However, the loss of 
this receptors in erythrocytes has been shown to reduce 
susceptibility or complete resistance to P. vivax infection 
[7, 8]. As a result studies have targeted the Duffy bind-
ing protein as a potential vaccine candidate, which would 
be capable of blocking entrance to its host [4]. In support 
of this hypothesis, several studies have shown that the 
polymorphic sites of the Duffy binding protein are local-
ized and that most of the sequence remains conserved 
[9]. This is largely down to the structural biology of the 
protein and the nature of its junction formation with the 
Duffy antigen for chemokine receptors [19]. In order to 
maintain this junction, the protein needs to maintain 
its structural rigidity as an alteration could lead to a loss 
of forming this critical network with its receptor [20]. 
Therefore, much of the region responsible for attachment 
is highly conserved. Instead, the protein shows polymor-
phism away from these regions, mostly on B and T cell 
epitopes or around them. The protein uses these poly-
morphic sites to exercise antigenic diversity, providing 
the protein the capability of immune evasion. Therefore, 
to use this protein as a vaccine, a multivalent vaccine 
approach is critical, i.e., the ability to cover the diversity 
of circulating strains globally. However much of these 
studies have focused on non-African strains, instead 
Table 4 Genetic differentiation (Fst) values of the pvdbpII gene among eight P. vivax endemic geographical populations
Ethiopia India Mexico Myanmar PNG South K Sri lanka Sudan
India 0.0422
Mexico 0.1940 0.2500
Myanmar 0.0846 0.0499 0.1458
PNG 0.1275 0.1180 0.2766 0.1314
South K 0.1301 0.1226 0.3647 0.1441 0.2454
Sri_lanka 0.0529 0.0193 0.2653 0.0826 0.1302 0.1158
Sudan 0.0945 0.1328 0.0673 0.0660 0.2239 0.1927 0.1495
Fig. 4 PvdbpII haplotypes observed among Ethiopian isolates.There 
were nine haplotypes observed from the 23 Ethiopian isolates (Fig. 4)
Fig. 5 Network analysis of pvdbpII haplotypes using the median 
joining algorithm implemented in Network software. The Pies 
represent the haplotypes with lines indicating the connections, 
size of each pie corresponds to frequency, and colors indicate the 
geographic populations
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targeting only on Asian, South American and Australian 
strains. This is counterproductive as Africa and particu-
larly Ethiopia is the one of the highest contributors to 
morbidity rates in the world [16]. Much remains unclear 
in terms of understanding the nature of the Duffy bind-
ing protein in Ethiopia, particularly circulating strains, 
nature of haplotypes and genetic diversity. Here for the 
first time, the haplotype diversity of pvdbpII and natural 
selection of Ethiopian PvDBPII and the haplotype preva-
lence based on predominant, non-synonymous single 
nucleotide polymorphisms (SNPs) are reported.
There were 10 nonsynonymous mutations in Ethio-
pian isolates, all of which mapped exclusively to epitopes 
regions. This was concurrent with observation with other 
global isolates; however, other isolates exhibited non-
synonymous mutation in other regions as well, albeit 
near the epitopes. This agrees with the hypothesis that 
immune pressure from the host is responsible for the 
diversifying selection occurring on this region. How-
ever, the extent of immune selection in Ethiopian isolates 
seems to be much more pronounced as evidenced from 
the departure of neutrality test. Indeed, significant posi-
tive values would indicate diversifying selection, whereas 
significantly negative values would indicate purifying 
selection. Analysis of Ethiopian isolates reveals signifi-
cant positive values for both Tajimas D and Fu and Lis f 
tests. Furthermore, both tests showed that selection was 
operating in the same location as the epitopes, confirm-
ing the immune selection hypothesis. This trend was also 
similar for global sequences although significantly posi-
tive values were not found for Ethiopian isolates. In com-
pliment, genetic diversity (π) was highest in two regions 
particularly that are found in the central domain of the 
protein. For Ethiopian isolates this ranged from 0.014 
to 0.019, a mark of localized diversity. This was also in 
complement to the departure of neutrality test which 
found significantly negative values in regions away from 
this peak diversity. It has been indicated that higher lev-
els of polymorphism may also reflect the artifact of dif-
ferences in sampling, PCR and/or sequencing, which 
may have caused South Korean isolates to have higher 
genetic diversity as compared to countries endemic with 
high vivax malaria such as Colombia and PNG [21, 22]. 
However, nucleotide diversity was moderate in Ethiopian 
isolates in relation to other countries, and only specific 
regions appeared to have significantly higher nucleotide 
diversity as such it is not expected to be a result of sam-
pling and/or sequencing artifacts.
Meiotic recombination has previously been indicated 
as a potential source of genetic variation in pvdbpII. 
Here recombination was evaluated using DnaSP mini-
mum recombination event parameter and as an indi-
rect indicator of Linkage disequilibrium. In the event 
of meiotic recombination, the frequency of linkage 
disequilibrium declines significantly with increasing 
distance. Indeed, linkage disequilibrium showed sig-
nificant decline in the analysed region suggesting a role 
for recombination. Similarly, DnaSP found regions that 
were recombining, although to a lesser extent in Ethio-
pian and South Korean isolates. It has been suggested 
that this could be a result of a declining P. vivax trans-
mission or an indication of malaria intervention (could 
be related to vivax seasonality or transmission strength) 
[22]. However other global population showed higher 
recombination values indicating the contribution of 
Recombination towards genetic diversity. This is in 
agreement with several other studies, which examined 
the effects of recombination in P. vivax endemic coun-
tries. As such it is also likely that the test used to detect 
recombination for Ethiopian isolates may not have suf-
ficient power to detect low recombination events. Low 
transmission can explain why recombination is low 
while balancing selection maintains the already high 
genetic diversity observed in Ethiopia, indeed sam-
ples were taken from low transmission setting and 
hence might explain why genetic diversity is high while 
recombination is low.
Fst index was used to assess the degree of popula-
tion differentiation and gene flow in the eight P. vivax 
endemic countries. Ethiopian isolates showed lower 
degree of differentiation with Indian isolates, perhaps 
unsurprisingly given the expanding P. vivax population 
and/or extensive gene flow supported by intense human 
migration between the two countries. On the other hand, 
little differentiation was also seen in Ethiopian and Sri 
Lankan isolates, Ethiopian and Sudanese isolates. It is 
also likely that the strong selection pressure resulted in 
low Fst values, as fixation of certain alleles may also affect 
the result [5]. Moreover, relatively high degree of differ-
entiation was exhibited between Ethiopian and Mexican, 
Ethiopian and Papua New Guinean, Ethiopian and South 
Korean isolates. This could be due to the geographic bar-
rier between the countries inhibiting gene flow. Indeed, 
Fst values exceeded 0.25 which would refer to highly dif-
ferentiated populations, in isolates from India PNG and 
South Korea vs Mexican isolates showing a reduced gene 
flow. Similarly, it is quite possible that the strong selec-
tion pressure exerted in this gene may have caused a 
fixation of alleles in certain geographic regions while 
remaining absent in others. It should be noted that Fst 
values are affected by factors such as population struc-
ture, where the test assumes a stable population struc-
ture which may not be the case for P. vivax infections. 
However other studies have indeed found population 
clustering in relation to geographic origin and distance, 
as confirmed using AMOVA and STRU CTU RE analysis, 
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similarly the same held true for Ethiopian isolates using 
STRU CTU RE analysis.
High numbers of haplotypes were found in the Ethio-
pian datasets, interestingly, this was like a recent global 
pvdbpII haplotype analysis study which previously identi-
fied seven haplotypes that can cover 60% parasite popu-
lation in 8 malaria endemic countries [9]. However, the 
previous study used isolates from non-African countries 
and recommended an inclusion of representative hap-
lotypes. Accordingly, few studies have explored genetic 
diversity of pvdbpII in African countries, such as Sudan. 
The study in Sudanese isolates found that only one unique 
haplotype was not included in global haplotype diversity 
[23]. The finding of this study show four unique haplo-
types in the Ethiopian isolates that were not shared with 
other global isolates, perhaps indicating that there are 
haplotypes that have not been considered for vaccine tri-
als. Indeed, the frequency of this haplotypes in this study 
in was not significant as three of the four only had one 
representative. Even so the low number of samples in this 
study compared to the number of haplotypes observed, 
will warrant further study. As such further studies on the 
frequency of circulating haplotypes in Ethiopia will give a 
clear indication as to which are the dominant strains that 
need be included for global vaccine trials.
Haplotype diversity was indeed high in most of the 
population included in this study, although it is much 
more pronounced in Sri Lankan and Indian isolates. In 
the Sri Lankan isolates haplotype diversity reach 1, show-
ing the extent of variability in the population. In Ethiopia, 
however, haplotype diversity was intermediate in relation 
to the other included population sets. Indeed, again a 
small number of samples included could have limited the 
power of the analysis, but even so the analysis found nine 
types of haplotypes from 23 Ethiopian isolates. Five of 
these haplotypes were part of the major haplotype cluster 
responsible for 36.7% of the global population included 
for this study. A total of 136 haplotypes were results of 
singleton mutations, hence the results support the pre-
viously mentioned study which identified seven haplo-
types that can cover 60% parasite population in 8 malaria 
endemic countries [9].
Subsequently this region was mapped to a recently 
experimentally validated tertiary structure of PvDBPII 
[20]. This structure was determined using a reliable X-ray 
diffraction method, as opposed to a previous homology 
modelled structure. This was advantageous as homology 
modelling is not as reliable as x ray diffraction. This may 
have affected a 2010 study which found a high genetic 
diversity and residues under strong positive selection 
near the DARC receptor domain [24]. This would result 
in the blockage of junction formation, virtually inhibit-
ing red cell invasion. Apart from this, the study stipulated 
that antibodies involved in invasion inhibitory activity 
also block PvDBP-DARC interaction. However recent 
studies on pvdbpII copy number amplification have 
shown that they are able to infect even in the presence 
of naturally acquired antibodies [18]. This would at least 
indicate the presence of other mechanism for immune 
evasion such as antigenic variation. This is also sup-
ported by subsequent worldwide studies, which have 
shown many mutations to be predominantly placed on 
epitopes which agreed with the results of this study [5, 9]. 
This result is further supported by departure of neutral-
ity tests and now a reliable tertiary structure of PvDBPII 
which placed non-synonymous mutations away from the 
DARC recognition site.
Conclusion
This study provides the first description on genetic diver-
sity; the prevalence and nature of pvdbpII sequence poly-
morphisms in Ethiopian field P. vivax isolates. The results 
of this study support the multivalent vaccine approach 
to design an effective treatment. However, the presence 
of novel haplotypes that were not shared by other global 
sequences warrant further investigation. As such addi-
tional studies need to be made to assess pvdbpII sequence 
polymorphism by collecting large number of clinical iso-
lates from various heterogenous regions of Ethiopia. This 
will be an important step in designing and developing an 
efficacious PvDBPII vaccine capable of covering global 
strains.
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